Finally, it has been suggested that the modulation of Akt could be a good strategy to increase the anti-tumor immunity for adoptive CAR T cell therapy, which could be translatable into the clinical activity with the availability of a pharmaceutically approved Akti [51] (Figure 3). This evidence concerns the gene AKT1 and neoplasm.